5 Key Medication Assisted Treatment Statistics to Consider

What the numbers are really telling you

If you're reading this, you've probably already heard the line: medication-assisted treatment is just trading one drug for another. Maybe a family member said it. Maybe you've said it to yourself at 2 a.m. when you couldn't sleep.

Set that aside for a minute. Not because the worry isn't real, but because the numbers tell a different story, and you deserve to see them clearly before you decide anything.

Five statistics keep showing up across CDC reports, NIH studies, and peer-reviewed research on MAT for opioid use disorder. Together they answer the quiet question underneath your search: does this actually work, and is it worth the effort of starting?

The short version is yes, with important specifics. MAT reduces the risk of dying after an overdose. It keeps people engaged in care long enough for real change to take hold. It lowers illicit opioid use and improves things like employment and mental health ¹. It's also badly underused, with only about a quarter of U.S. adults who need it actually receiving it ³. And as access has expanded, overdose deaths in the U.S. have started falling for the first time in years ⁵.

What follows isn't a lecture. It's five numbers, each paired with what it could mean for your Tuesday morning, your job, your relationships, your next ninety days. Choosing to look at them takes courage. You're already doing the harder part.

A 59% drop in overdose deaths after methadone, 38% after buprenorphine

Start with the number that matters most when you're scared.

A large population-based study tracked people who had already survived a nonfatal opioid overdose, then followed them for twelve months. Compared with people who received no medication, opioid overdose deaths fell by 59% for those receiving methadone and 38% for those receiving buprenorphine ². That's not a small effect. That's the difference between a second chance and a phone call your family never wants to get.

Read that scope carefully, because it matters. This study didn't ask whether MAT works for everyone in every situation. It asked a sharper question: after someone has already overdosed once and lived, does starting medication change what happens next? The answer was yes, by a wide margin, for both medications studied ².

If you or someone you love has been through an overdose, that finding is for you. The risk of a second overdose after the first one is the part nobody wants to talk about at the kitchen table. These medications cut that risk substantially. Not by a little. By more than half, in the case of methadone.

Here's what that can look like on a regular Wednesday. You wake up. You take your medication, either at a clinic or at home depending on the option you're on. The craving that used to hijack your morning is quieter—not always gone, but quieter. You make it to work. You have lunch with a coworker without scanning the parking lot. You go to a counseling session after your shift. You sleep. None of that sounds dramatic. That's the point. The drama is what isn't happening: the relapse, the ER visit, the call to your mother.

You might wonder why the two numbers are different. Methadone and buprenorphine work in slightly different ways, and they fit different lives. Methadone is dispensed daily at a licensed clinic, which can feel like a lot but also creates structure that some people need early on. Buprenorphine can often be prescribed and taken at home, which works better for people whose schedules or family responsibilities make daily clinic visits hard. Neither is better in every case. The right one is the one you'll actually stay on, with a clinician who knows your story.

One more thing about that 59% and 38%. The study compared medication to no medication. It did not compare medication to willpower, to a residential program, or to a meeting at the church basement. Those things can be part of recovery too. But if you've already survived an overdose, the data is asking you to consider adding medication to whatever else you're doing, not to replace the parts that help you feel human. In an outpatient program, that's exactly the pairing: the medication that lowers the biological risk, plus the counseling, skill-building, and trauma-informed support that help the rest of life catch up.

You don't have to be certain to start. You just have to be willing to look at the number and let it count for something.

Only about 1 in 4 adults who need OUD medication actually get it

Here's the number that should make you angry, or at least give you permission to stop blaming yourself for not having figured this out sooner.

In 2022, an estimated 9.37 million U.S. adults needed treatment for opioid use disorder. Of those, only 25.1% received medications for OUD. Another 30% got treatment without medication, and 44.9% received no treatment or unspecified care ³. A separate peer-reviewed analysis put the range at 22% to 28% of people who would benefit from MOUD actually receiving it in a given year ⁴. Two different studies, two different methods, roughly the same answer.

One in four. Maybe a little more, maybe a little less, depending on the year and the state.

Sit with that for a second. If MAT cuts overdose deaths by more than half in some populations, and three out of four people who need it aren't getting it, then the biggest barrier to recovery in this country isn't whether the treatment works. It's whether people can find it, afford it, fit it into their lives, and feel okay walking through the door.

That's not a personal failing. That's a system gap. And if you've been hard on yourself for not starting sooner, or for trying something that didn't stick, the numbers are telling you something honest: most people in your shoes never even get offered the option that the research most strongly supports.

Why the gap? A few reasons keep showing up in the research. Stigma is a big one—both inside families and inside doctors' offices. A lot of adults don't perceive they need treatment, often because the framing they've heard treats medication as cheating ³. Geography is another. In rural areas and even in plenty of cities, the nearest methadone clinic might be an hour's drive, and the nearest buprenorphine prescriber might have a months-long waitlist. Insurance can be a maze. Work schedules collide with clinic hours. Childcare collides with everything.

None of that is your fault. It is the reality you're working inside.

What this means for your week is more practical than philosophical. If you're going to be one of the people who actually gets the medication that the data points to, you probably need to find a program that has already solved a few of these problems for you. That looks like flexible scheduling—morning, afternoon, or evening groups so you don't have to choose between treatment and your paycheck. It looks like a clinician who can prescribe buprenorphine on-site rather than sending you to a separate office. It looks like care coordination, so somebody else helps untangle the insurance call and the prior authorization. It looks like outpatient care, so you can sleep in your own bed and keep showing up for the people who count on you.

You don't have to fix the national gap. You just have to find a door that's open on a day you can walk through it. The fact that you're reading this means you're closer to that door than three quarters of the people who need to be.

Staying in treatment six months changes more than urine screens

A lot of programs measure success by what shows up on a drug test. That's a real measurement, and it matters. But it isn't the only thing that changes when someone stays in MAT long enough for the medication, the counseling, and the rest of life to start working together.

A peer-reviewed study followed patients in a MAT pilot program for six months. The ones who were still in treatment at that point showed clinically meaningful reductions in opioid, alcohol, and other drug use. They also reported better physical and mental health, lower anxiety and depression symptoms, and improvements in employment indicators ¹⁰. A separate HHS review of MAT models reached a similar conclusion from a different angle: retention in MAT is associated with reduced mortality and better continuity of care across the long arc of recovery ⁸.

Sit with what "six months" actually means. Not six months of perfection. Six months of showing up. Six months of taking the medication most days, sitting in a counseling chair most weeks, and choosing the harder thing more often than not. The research isn't measuring sainthood. It's measuring whether you stayed in the room.

Here's where the urine screen stops being the whole story. Imagine you've been on MAT for six months. Your last screen is clean. Good. But also: you slept seven hours last night for the first time in two years. You called your sister back the same day. Your boss noticed you stopped flinching when she walked over to your desk. You picked up your kid from school without doing math in your head about whether you'd make it. None of that prints out on a lab report. All of it is what the data is actually catching when it talks about "improved health, employment, and reduced symptoms" ¹⁰.

The anxiety and depression piece deserves its own moment. Opioid use disorder almost never travels alone. Most people carrying it are also carrying something else—old trauma, untreated depression, an anxiety that started long before the first pill. When the medication quiets the craving, the other stuff doesn't disappear. It surfaces. That's why the research keeps pointing to the same answer: medication plus counseling, not medication alone. The six-month outcomes weren't from people who got a prescription and went home. They were from people who got the medication and the therapy and the check-ins and the help untangling what was underneath ¹⁰.

If you've tried treatment before and it didn't stick, the retention number might land hard. You might read "six months" and think, I couldn't even do six weeks. That's worth saying out loud: the research isn't a judgment on anyone who left early. It's a description of what becomes possible when the program is built to keep you there. Flexible scheduling so a 7 a.m. shift doesn't end your treatment. Evening groups for the parent who can't be away during homework hours. Trauma-informed counseling that doesn't ask you to repeat your worst day to a stranger on intake. Care coordination that handles the insurance phone tree so you can handle the actual work of recovery.

Retention is a system outcome, not a willpower outcome. The places where six-month numbers look the best are the ones that quietly removed the reasons people quit.

One more thing worth naming. The six-month window isn't a finish line. It's a hinge. The HHS review notes that longer retention keeps improving outcomes, and there's no single answer about how long someone should stay on MAT ⁸. Some people taper after a year. Some stay on medication for many years and live full, ordinary lives. Neither path is failure. The point of the statistic isn't to lock you into a timeline. It's to tell you that the first six months are where most of the heavy lifting happens, and the people who stay get to keep what they built.

Survival, retention, illicit use, employment, birth outcomes—one therapy, five levers

Picture a control panel with five sliders. Survival. Retention in care. Illicit opioid use. Employment. Birth outcomes for pregnant patients. Most treatments move one or two of those sliders. MAT, according to the federal agency that oversees substance use treatment policy, moves all five.

SAMHSA's official guidance describes medication-assisted treatment as an evidence-based approach that improves patient survival, increases retention in treatment and recovery services, decreases illicit opioid use and other illicit activity, improves the ability to get and keep a job, and improves birth outcomes among pregnant patients with substance use disorders ¹. That's not a marketing list. That's a federal agency naming what the research has shown, across studies and over time.

It's worth slowing down on each one, because they don't mean the same thing to every reader.

• Survival is the floor. If you're not alive, none of the other sliders matter. The mortality reduction data already covered the size of that effect for people who survived an overdose ². The point here is that survival isn't a single statistic—it's the foundation the other four sit on.
• Retention is the quiet engine. People who stay in treatment longer get more of what treatment offers. They build a relationship with a counselor. They learn what their cravings actually look like instead of just reacting to them. They get the chance to be honest with someone more than once. The HHS review on MAT models found retention itself was associated with better outcomes across the board ⁸.
• Illicit opioid use going down is the slider most people picture when they think "treatment working." It's the urine screen, the missing pill bottle in the bathroom, the call that doesn't come at midnight. The MAT pilot study found significant reductions in opioid use, alcohol use, and other drug use at six months ¹⁰. Worth saying: alcohol use went down too. Most people with opioid use disorder are managing other substances alongside it, and the integrated approach tends to move those together.
• Employment is the slider nobody talks about until it shifts. Holding a job means more than a paycheck. It means a schedule, a reason to set an alarm, coworkers who notice you, the dignity of being depended on. The same pilot showed measurable improvements in employment indicators among people retained in treatment ¹⁰. SAMHSA includes job stability in its core list of MAT benefits for the same reason ¹.
• Birth outcomes are the slider most often left out of casual conversations about MAT, and they deserve a sentence of their own. For pregnant patients with opioid use disorder, MAT is associated with better outcomes for both parent and baby compared with untreated OUD ¹. That's the kind of fact that changes a family conversation when it lands at the right moment.

Five levers, one therapy. Whichever one matters most to you this week—staying alive, staying in the room, staying clean, staying employed, or protecting a pregnancy—the same integrated approach is moving it.

Overdose deaths fell 24% in a single year, and MAT is part of why

For years, the overdose chart only moved in one direction. Up. Every annual report from the CDC seemed to end the same way: more deaths than last year, more families changed forever, more reasons to feel like nothing was working.

Then the line bent.

Provisional CDC data showed U.S. drug overdose deaths declined nearly 24% for the 12 months ending September 2024 compared with the previous year—roughly 87,000 deaths versus around 114,000 the year before ⁵. A separate CDC Data Brief on 2023–2024 mortality found the national age-adjusted overdose death rate dropped 26.2% year over year ⁶. That's the steepest decline in decades. It came after a stretch when opioids were involved in about 76% of all drug overdose deaths in 2023, meaning the crisis driving most of those numbers was an opioid crisis ⁷.

The CDC is careful about causation, and so should we be. Nobody is saying MAT alone bent the curve. Naloxone distribution mattered. Fentanyl supply shifts mattered. Public health funding mattered. But expanded access to evidence-based treatment, including medications for opioid use disorder, is named directly in the CDC's own framing of why the numbers moved ⁵. The therapy that cuts post-overdose mortality by 38% to 59% in individual patients ² doesn't stop working when you zoom out to the country. It scales.

What that means for you is harder to hold than a single statistic, so try it this way. The year you've been deciding whether to start MAT is the same year tens of thousands of people didn't die who, by the prior trajectory, statistically should have. Some of them are on medication right now. Some of them are sitting in a Tuesday morning counseling group. Some of them are back at work. Some of them are sleeping in their own beds tonight because something in the system finally reached them in time.

That's not a guarantee about your story. It's a reason to take your story seriously enough to look at the option the evidence keeps pointing to.

There's a temptation, when the news is finally better, to relax. Don't. A 24% decline still leaves roughly 87,000 people who died in a single year ⁵. The 22–28% utilization gap for MOUD hasn't closed ⁴. The treatment that's helping bend the curve is still reaching only about one in four of the people who need it ³. Progress and shortfall are sitting in the same room.

The honest read is this. The national numbers are telling you that recovery, on the scale of millions of people, is possible right now in a way it wasn't five years ago. The same medications and integrated care models that show up in the mortality studies, the retention research, and the quality-of-life outcomes are part of why fewer families got the worst phone call this year than last year ^{5, 2, 8}. You don't have to believe in trends to act on that. You just have to believe your own life counts inside one.

Whatever's been keeping you stuck—stigma, scheduling, the voice in your head that says people like you don't get better—the data has stopped agreeing with it. People like you are getting better. In numbers large enough to move a national chart for the first time in a long time.

You're allowed to be one of them.

What an honest next step looks like this week

You don't have to decide your whole recovery today. You just have to decide what happens before Sunday night.

Pick one phone call. That's the next step. Maybe it's to an outpatient program that offers MAT alongside counseling so you only have to tell your story once. Maybe it's to your primary care doctor to ask who they trust locally. Maybe it's to the family member who has been waiting for you to bring this up first. One call. Not five.

You've already done the hard part by reading the numbers honestly. The team at Coastal Recovery Partners answers their phone, and so do plenty of others. Pick one. Make the call this week. That's the whole next step.

References

1. Treatment Options for Substance Use Disorder. https://www.samhsa.gov/substance-use/treatment/options
2. Methadone and buprenorphine reduce risk of death after opioid overdose. https://www.nih.gov/news-events/news-releases/methadone-buprenorphine-reduce-risk-death-after-opioid-overdose
3. Treatment for Opioid Use Disorder: Population Estimates, 2022. https://www.cdc.gov/mmwr/volumes/73/wr/mm7325a1.htm
4. Statewide Trends in Medications for Opioid Use Disorder Utilization and Disparities. https://pmc.ncbi.nlm.nih.gov/articles/PMC12661415/
5. CDC Reports Nearly 24% Decline in U.S. Drug Overdose Deaths. https://www.cdc.gov/media/releases/2025/2025-cdc-reports-decline-in-us-drug-overdose-deaths.html
6. Drug Overdose Deaths in the United States, 2023–2024. https://www.cdc.gov/nchs/products/databriefs/db549.htm
7. Understanding the Opioid Overdose Epidemic. https://www.cdc.gov/overdose-prevention/about/understanding-the-opioid-overdose-epidemic.html
8. Models for Medication-Assisted Treatment for Opioid Use Disorder: Retention, Continuity of Care, and Other Outcomes. https://aspe.hhs.gov/reports/models-medication-assisted-treatment-opioid-use-disorder-retention-continuity-care-0
9. Medication-Assisted Treatment for Opioid Use Disorder: A Guide for Employers. https://www.cdc.gov/niosh/docs/wp-solutions/2019-133/pdfs/2019-133.pdf
10. Outcomes from the medication assisted treatment pilot program for opioid use disorder. https://pmc.ncbi.nlm.nih.gov/articles/PMC8722086/